Diabetes promotes the development of both heart failure with a reduced ejection fraction
and heart failure with a preserved ejection fraction through diverse mechanisms, which are …

Background Metabolic syndrome and related metabolic disturbances represent a state of
low-grade inflammation, which accelerates insulin resistance, type 2 diabetes (T2D) and …

Background Large clinical trials established the benefits of sodium-glucose cotransporter 2
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …

Objectives The goal of this study was to evaluate the effect of empagliflozin, in addition to
optimal medical treatment, on epicardial adipose tissue (EAT), interstitial myocardial fibrosis …

Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …

Background The relationship between the benefits of empagliflozin in heart failure with
reduced ejection fraction (HFrEF) and N-terminal pro–B-type natriuretic peptide (NT …

Background: SGLT2i (sodium-glucose cotransporter-2 inhibitors) improve clinical outcomes
in patients with heart failure, but the mechanisms of action are not completely understood …

Background Sodium‐glucose cotransporter‐2 inhibitors are cardioprotective independent of
glucose control, as demonstrated in animal models of acute myocardial ischemia and …

Objectives The use of sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) has resulted in
significant benefits in patients with heart failure irrespective of left ventricular ejection fraction …

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment
strategy for heart failure with reduced ejection fraction (HFrEF) and—depending on the …